Arrowhead Pharmaceuticals (ARWR) vs Madrigal Pharmaceuticals (MDGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Arrowhead Pharmaceuticals (ARWR) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 68.3% versus a gain of 11.8%. Over five years, MDGL leads with a +466.0% price change compared with -7.1% for ARWR. Madrigal Pharmaceuticals is the larger company by market cap ($11.05 billion vs $8.42 billion), about 1.3 times the size, while Arrowhead Pharmaceuticals is growing revenue faster (+23258.2% vs +432.1%).
Arrowhead Pharmaceuticals converts more of its revenue into profit, with a net margin of -0.2% versus -30.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARWR | MDGL |
|---|---|---|
| Share price | $59.64 | $478.24 |
| Market cap | $8.42B | $11.05B |
| 1-day change | -2.99% | -1.94% |
| YTD return | -7.40% | -16.25% |
| 1-year return | +68.25% | +11.79% |
| 5-year return | -7.07% | +466.00% |
| Forward P/E | — | 49.69 |
| EPS (TTM) | $-2.28 | $-12.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $829.45M | $958.40M |
| Revenue growth (YoY) | +23258.15% | +432.05% |
| Net income (latest FY) | $-1.63M | $-288.28M |
| Operating margin | 11.86% | -31.31% |
| Net margin | -0.20% | -30.08% |
| 52-week high | $95.49 | $615.00 |
| 52-week low | $34.61 | $393.61 |
| Distance from 52-week high | -37.54% | -22.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +79.80% | +42.63% |
| Average volume | 1.90M | 289.31K |
| Shares outstanding | 141.25M | 23.10M |
| Employees | 711 | 915 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARWR has outperformed MDGL by 56.5 percentage points over the past year.
- Arrowhead Pharmaceuticals is more profitable, keeping -0.2 cents of every revenue dollar as net income versus -30.1 cents for Madrigal Pharmaceuticals.
- Arrowhead Pharmaceuticals grew revenue faster in its latest fiscal year (+23258.15% vs +432.05%).
About Arrowhead Pharmaceuticals
ARWR stock →Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 711 employees
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
ARWR vs MDGL FAQ
Which is bigger, Arrowhead Pharmaceuticals or Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals (MDGL) is larger, with a market capitalization of $11.05B compared with $8.42B for Arrowhead Pharmaceuticals (ARWR).
Which stock has performed better over the past year, ARWR or MDGL?
ARWR returned +68.25% over the past 12 months, compared with +11.79% for MDGL (price return, excluding dividends). Past performance does not predict future results.
Are Arrowhead Pharmaceuticals and Madrigal Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.